Randomized Comparison Between Radial and Femoral Large-Bore Access for Complex Percutaneous Coronary Intervention.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
28 06 2021
Historique:
received: 04 01 2021
revised: 18 03 2021
accepted: 23 03 2021
pubmed: 23 5 2021
medline: 29 10 2021
entrez: 22 5 2021
Statut: ppublish

Résumé

The aim of this study was to investigate whether transradial (TR) percutaneous coronary intervention (PCI) is superior to transfemoral (TF) PCI in complex coronary lesions with large-bore guiding catheters with respect to clinically relevant access site-related bleeding or vascular complications. The femoral artery is currently the most applied access site for PCI of complex coronary lesions, especially when large-bore guiding catheters are required. With downsizing of TR equipment, TR PCI may be increasingly applied in these patients and might be a safer alternative compared with the TF approach. An international prospective multicenter trial was conducted, randomizing 388 patients with planned PCI for complex coronary lesions, including chronic total occlusion, left main, heavy calcification, or complex bifurcation, to either 7-F TR access (TRA) or 7-F TF access (TFA). The primary endpoint was defined as access site-related clinically significant bleeding or vascular complications requiring intervention at discharge. The secondary endpoint was procedural success. The primary endpoint event rate was 3.6% for TRA and 19.1% for TFA (p < 0.001). The crossover rate from radial to femoral access was 3.6% and from femoral to radial access was 2.6% (p = 0.558). The procedural success rate was 89.2% for TFA and 86.0% for TRA (p = 0.285). There was no difference between TFA and TRA with regard to procedural duration, contrast volume, or radiation dose. In patients undergoing PCI of complex coronary lesions with large-bore access, radial compared with femoral access is associated with a significant reduction in clinically relevant access-site bleeding or vascular complications, without affecting procedural success. (Complex Large-Bore Radial Percutaneous Coronary Intervention [PCI] Trial [Color]; NCT03846752).

Sections du résumé

OBJECTIVES
The aim of this study was to investigate whether transradial (TR) percutaneous coronary intervention (PCI) is superior to transfemoral (TF) PCI in complex coronary lesions with large-bore guiding catheters with respect to clinically relevant access site-related bleeding or vascular complications.
BACKGROUND
The femoral artery is currently the most applied access site for PCI of complex coronary lesions, especially when large-bore guiding catheters are required. With downsizing of TR equipment, TR PCI may be increasingly applied in these patients and might be a safer alternative compared with the TF approach.
METHODS
An international prospective multicenter trial was conducted, randomizing 388 patients with planned PCI for complex coronary lesions, including chronic total occlusion, left main, heavy calcification, or complex bifurcation, to either 7-F TR access (TRA) or 7-F TF access (TFA). The primary endpoint was defined as access site-related clinically significant bleeding or vascular complications requiring intervention at discharge. The secondary endpoint was procedural success.
RESULTS
The primary endpoint event rate was 3.6% for TRA and 19.1% for TFA (p < 0.001). The crossover rate from radial to femoral access was 3.6% and from femoral to radial access was 2.6% (p = 0.558). The procedural success rate was 89.2% for TFA and 86.0% for TRA (p = 0.285). There was no difference between TFA and TRA with regard to procedural duration, contrast volume, or radiation dose.
CONCLUSIONS
In patients undergoing PCI of complex coronary lesions with large-bore access, radial compared with femoral access is associated with a significant reduction in clinically relevant access-site bleeding or vascular complications, without affecting procedural success. (Complex Large-Bore Radial Percutaneous Coronary Intervention [PCI] Trial [Color]; NCT03846752).

Identifiants

pubmed: 34020929
pii: S1936-8798(21)00513-6
doi: 10.1016/j.jcin.2021.03.041
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT03846752']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1293-1303

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Terumo EMEA supported this investigator-initiated study with an unrestricted grant. Drs. van Leeuwen, Aminian, Dens, and Iglesias are consultants for Terumo. Drs. Iglesias and Schmitz have received honoraria and speaker fees from Terumo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Thomas A Meijers (TA)

Department of Cardiology, Isala Heart Center, Zwolle, the Netherlands.

Adel Aminian (A)

Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium.

Marleen van Wely (M)

Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.

Koen Teeuwen (K)

Department of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.

Thomas Schmitz (T)

Department of Cardiology, Elisabeth Krankenhaus, Essen, Germany.

Maurits T Dirksen (MT)

Department of Cardiology, Northwest Clinics, Alkmaar, the Netherlands.

Sudhir Rathore (S)

Department of Cardiology, Frimley Health NHS Foundation Trust, Surrey, United Kingdom.

René J van der Schaaf (RJ)

Department of Cardiology, Onze Lieve Vrouwe Gasthuis Hospital, Amsterdam, the Netherlands.

Paul Knaapen (P)

Department of Cardiology, VU University Medical Center, Amsterdam, the Netherlands.

Joseph Dens (J)

Department of Cardiology, Hospital Oost-Limburg, Genk, Belgium.

Juan F Iglesias (JF)

Department of Cardiology, Geneva University Hospital, Geneva, Switzerland.

Pierfrancesco Agostoni (P)

Department of Cardiology, ZNA Middelheim, Antwerp, the Netherlands.

Vincent Roolvink (V)

Department of Cardiology, Isala Heart Center, Zwolle, the Netherlands.

Renicus S Hermanides (RS)

Department of Cardiology, Isala Heart Center, Zwolle, the Netherlands.

Niels van Royen (N)

Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.

Maarten A H van Leeuwen (MAH)

Department of Cardiology, Isala Heart Center, Zwolle, the Netherlands. Electronic address: m.a.h.van.leeuwen@isala.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH